维普期刊资源整合服务平台（V6.5）

28篇 您的检索式：作者名="Hompesch M"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemie control and lowers body weight in subjects with type 2 diabetes显示文摘	Nauck MA Hompesch M Filipczak R	2006	Exp Clin Endocrinol Diabetes2006，114，8：	1
2	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes显示文摘	Nanck MA Hompesch M Filipczak R	2006	Exp Clin Endocrinol Diabet2006，114，8：	1
3	Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not op- timally controlled on insulin 显示文摘	Devineni D Morrow L Hompesch M	2012	Diabetes Obes Metab2012，14，6：	1
4	A novel insulin formulation with a more rapid onset of action 显示文摘	Steiner S Hompesch M Pohl R	2008	Diabetologia2008，51，9：	1
5	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes显示文摘	Nauck M A Hompesch M Filipczak R	2006	Exp Clin Endocrinol Dibetes2006，114，8：	1
6	Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin 显示文摘	DEVINENI D MORROW L HOMPESCH M	2012	Diabetes Obes Metab2012，14，6：	1
7	Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm显示文摘	Krentz A J Morrow L Hompesch M	2012	Drugs2012，72，13：	1
8	Noimpairment of hypoglycaemia counterregulation via glucagon with the long acting GLP-I derivative, NN2211, in subjects with type 2 diabetes显示文摘	Nauck M E1-Ouaghlidi A Hompesch	2003	Diabetologia2003，46，2：	1
9	Canaglifloz-in improves glycaemic control over 28 days in subjects with type 2diabetes not optimally controlled on insulin 显示文摘	DEVINENI D MORROW L HOMPESCH M	2012	Diabetes ObesMetab2012，14，6：	1
10	Developing new drugs for di- abetes and cardiometabolic disorders : a changing paradigm 显示文摘	Krentz AJ Morrow L Hompesch M	2012	Drugs2012，72，13：	1
11	Co-administration of liraglutide with insulin detemir demonstrates additive pharma- codynamic effects with no pharmacokinetic interaction 显示文摘	Morrow L Hompesch M Guthrie H	2011	Diabetes Obes Metab2011，13，1：	1
12	Co-administration of liraglu- tide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction 显示文摘	Morrow L Hompesch M Guthrie H	2011	Diabetea Obes Metab2011，13，：	1
13	Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American,w hite,and Hispanic/Latino patients w ith type 2 diabetes mellitus显示文摘	Hompesch M Morrow L Watkins E	2014	Clin Ther2014，36，4：	1
14	Five weeks of treatment with the GLP-l analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes显示文摘	Nauck MA Hompesch M Filipczak R	2006	Experimental and Clinical Endocrinology and Diabetes2006，114，：	1
15	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes显示文摘	NAUCK MA HOMPESCH M FILIPCZAK R	2006	Exp Clin Endocrinol Diabetes2006，114，：	1
16	Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes显示文摘	Nauck MA Hompesch M Filipczak R	2006	Exp Clin Endocrinol Diabetes2006，114，8：	1
17	Liraglutide significantly improves glycemic control and reduces body weight compared with ghmcplridc as add-on to mefformin in type 2 diabetes(abstr) 显示文摘	Nauck M Hompesch M Filipczak R	2004	Diabetes2004，53，2：	1
18	Five weeks oftreatment with the GLP-1 analogue liraglutide improves glycaemiccontrol and lowers body weight in subjects with type 2 diabetes显示文摘	Nauck MA Hompesch M Filipczak R	2006	Exp Clin Endocrinol Diabetes2006，114，8：	1
19	Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups显示文摘	HOMPESCH M TROUPIN B HEISE T	2006	Diabetes Obes Metab2006，8，5：	1
20	Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction显示文摘	Morrow L Hompesch M Guthrie H		0，，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示